AI Article Synopsis
- Helicoid peripapillary chorioretinal degeneration (HPCD) is a hereditary eye disease causing progressive degeneration of the retina from the optic disc towards the macula and periphery, starting early in life.
- An elderly patient diagnosed with HPCD developed choroidal neovascular membrane (CNV) in both eyes, which is uncommon for this condition.
- Treatment with ranibizumab resulted in a good response, with significant improvements in visual acuity after just a few injections, highlighting that while HPCD usually doesn't lead to CNV, it can happen and respond well to treatment.
Article Abstract
Purpose: Helicoid peripapillary chorioretinal degeneration (HPCD) is a hereditary disease of the fundus that is characterized by atrophic chorioretinal areas that appear early in life and expand gradually from the optic disc towards the macula and the periphery.
Methods: We describe the case of an elderly man with a known diagnosis of HPCD who developed choroidal neovascular membrane (CNV) in both eyes during the course of the disease.
Results: The patient was treated with intravitreal injection of ranibizumab, to which he had excellent response. The CNV subsided with 2 injections in the right eye and 1 in the left. Two years after the initial diagnosis of CNV in the right eye, visual acuity was 5/10 OD and 9/10 OS.
Conclusions: Helicoid peripapillary chorioretinal degeneration is rarely complicated by CNV as the fundus lacks the trigger factors that would sustain this process. Although rare, HPCD complicated by CNV can be seen bilaterally, but responds well to few ranibizumab injections.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5301/ejo.5000695 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!